BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32515880)

  • 1. Mechanisms for increased risk of diabetes in chronic liver diseases.
    Svegliati-Baroni G; Gaggini M; Carli F; Barbieri C; Cucco M; Youne R; Rosso C; Bugianesi E; Gastaldelli A
    Liver Int; 2020 Oct; 40(10):2489-2499. PubMed ID: 32515880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.
    Coccia F; Testa M; Guarisco G; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
    Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):106-113. PubMed ID: 31677889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    Morio R; Hyogo H; Hatooka M; Morio K; Kan H; Kobayashi T; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Aikata H; Ochi H; Masayasu Y; Chayama K
    J Gastroenterol; 2017 Feb; 52(2):253-262. PubMed ID: 27351871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of insulin release and insulin sensitivity through oral glucose tolerance test: differences between NGT, IFG, IGT, and type 2 diabetes mellitus. A cross-sectional and follow-up study.
    Pontiroli AE; Pizzocri P; Caumo A; Perseghin G; Luzi L
    Acta Diabetol; 2004 Jun; 41(2):70-6. PubMed ID: 15224208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
    Firneisz G; Varga T; Lengyel G; Fehér J; Ghyczy D; Wichmann B; Selmeci L; Tulassay Z; Rácz K; Somogyi A
    PLoS One; 2010 Aug; 5(8):e12226. PubMed ID: 20805868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deterioration of insulin release rate response to glucose during oral glucose tolerance test is associated with an increased risk of incident diabetes in normal glucose tolerance subjects.
    Li Y; He S; Sun Y; Li G; Xu Q; Wang C; Jia W
    IUBMB Life; 2017 Sep; 69(9):756-766. PubMed ID: 28762247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease.
    Grancini V; Trombetta M; Lunati ME; Zimbalatti D; Boselli ML; Gatti S; Donato MF; Resi V; D'Ambrosio R; Aghemo A; Pugliese G; Bonadonna RC; Orsi E
    J Hepatol; 2015 Dec; 63(6):1484-90. PubMed ID: 26297917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of steatosis on insulin secretion in chronic hepatitis C patients.
    Narita R; Abe S; Tabaru A; Otsuki M
    Am J Gastroenterol; 2007 Oct; 102(10):2173-80. PubMed ID: 17680843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study.
    Henninger J; Hammarstedt A; Rawshani A; Eliasson B
    BMC Endocr Disord; 2015 Sep; 15():51. PubMed ID: 26407933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose.
    Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4717-23. PubMed ID: 23066121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Bugianesi E; Bouserhal T; Marini F; Ridolfi F; Tarsetti F; Ancarani F; Petrelli E; Peruzzi E; Lo Cascio M; Rizzetto M; Marchesini G; Benedetti A
    Gut; 2007 Sep; 56(9):1296-301. PubMed ID: 17392334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease.
    Sesti G; Hribal ML; Fiorentino TV; Sciacqua A; Perticone F
    BMJ Open Diabetes Res Care; 2014; 2(1):e000016. PubMed ID: 25452862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD).
    Hatziagelaki E; Herder C; Tsiavou A; Teichert T; Chounta A; Nowotny P; Pacini G; Dimitriadis G; Roden M
    PLoS One; 2015; 10(5):e0124935. PubMed ID: 25933030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of future diabetes is as high with abnormal intermediate post-glucose response as with impaired glucose tolerance.
    Viswanathan V; Clementina M; Nair BM; Satyavani K
    J Assoc Physicians India; 2007 Dec; 55():833-7. PubMed ID: 18405128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visceral adipose tissue accumulation and cardiovascular disease risk profile in postmenopausal women with impaired glucose tolerance or type 2 diabetes.
    Lemieux S; Bédard A; Piché MÈ; Weisnagel SJ; Corneau L; Bergeron J
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):340-5. PubMed ID: 21092050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
    Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
    Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose.
    Maagensen H; Junker AE; Jørgensen NR; Gluud LL; Knop FK; Vilsbøll T
    J Clin Endocrinol Metab; 2018 May; 103(5):2042-2049. PubMed ID: 29506157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
    Gastaldelli A
    Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.